Infectious Disease Molecular Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents), By Technology (Mass Spectrometry, PCR, In Situ Hybridization), By Application, By End-use, By Region, And Segment Forecasts, 2025 - 20

Infectious Disease Molecular Diagnostics Market Growth & Trends

The global infectious disease molecular diagnostics market size is expected to reach USD 20.15 billion by 2030, registering a CAGR of 3.37% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by the introduction of technologically advanced products and an increase in demand for molecular diagnostics in PoC settings.

Rapid technological advancements with portability, accurate results, and cost-effectiveness are anticipated to serve as crucial drivers of the market for infectious disease molecular diagnostics. Companies are upgrading their products by implementing new techniques to gain specific and accurate results. Key players are updating their product portfolio for PCR instruments with increased R&D initiatives for developing novel kits to target emerging diseases or by entering into agreements with other kit manufacturing companies.

Technologies such as INAAT, mass spectroscopy, and ISH are advanced and have a low false-positive rate as compared to other traditional diagnostic tests. Advantages such as the cost-effectiveness and user-friendliness of this technology and the accuracy offered are estimated to increase the adoption of this technology.

The use of molecular diagnostics in research institutes is increasing. The use of techniques such as PCR, western blotting, and southern blotting is becoming common. Moreover, the spread of SARS-CoV-2 infection globally has led to an increase in research funding by governments as well as diagnostic companies to search for innovative molecular diagnostics.

Molecular diagnostics deliver effective and accurate results. Moreover, these tests enable the early detection of diseases, maintaining a low threat of substitutes. However, the high prices of these tests are expected to encourage patients to shift to external substitutes. Moreover, for the detection of newer infections such as SARS-CoV-2, the rate of internal substitution is high, which boosts competitive rivalry.

Infectious Disease Molecular Diagnostics Market Report Highlights

• Reagents led the market with a 25.86% revenue share in 2024 and are projected to experience the fastest CAGR over the forecast period due to their widespread use in infectious disease diagnostics.
• Polymerase Chain Reaction (PCR) technology secured the dominant revenue share in 2024 owing to its widespread application in detecting a broad range of infectious diseases, including COVID-19, HIV, hepatitis, and tuberculosis.
• Respiratory diseases held the largest market share of 71.96% in 2024, driven primarily by the rising prevalence of respiratory infectious diseases such as Respiratory Syncytial Virus (RSV), influenza, COVID-19, etc.
• Diagnostic laboratories held the dominant revenue share in 2024, driven by the rising prevalence of infectious diseases such as HIV, hepatitis, tuberculosis, and respiratory infections, which require accurate and timely diagnosis.
• North America infectious disease molecular diagnosis market accounted for 40.95% of the revenue share in 2024, driven by the high prevalence of infectious diseases such as COVID-19, influenza, HIV, and hepatitis.